Compare Omnicom Group Inc. (OMC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Omnicom Group Inc. trades at $76.48 (market cap $20.97B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays the higher dividend (4.19%). Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 63 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| OMC | ZBH | |
|---|---|---|
Market Cap | $20.97B | $16.95B |
Volume | 2,092,899 | 2,505,240 |
Sector | Media | Health |
52-Week High | $88.94 | $103.98 |
52-Week Low | $67.27 | $79.58 |
Typical Hold Time | 63 Days | 89 Days |
Enterprise Value | $29.05B | $24.02B |
Dividend Yield | 4.19% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $76.45, up 2.11% with a bullish technical signal despite mixed earnings performance. The company shows strong revenue growth to $17.27B in 2025 but reported a net loss of -$54.5M. Analyst consensus is mixed with 32% buy ratings and a $100.50 price target, while recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings.
OMC presents a value opportunity with attractive P/S of 0.86 and dividend yield, though high P/E of 206.62 and recent net loss pose risks. Upside potential exists from AI capabilities and post-Interpublic synergies, but advertising market weakness and debt levels require monitoring for sustained recovery.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
